Summary
LLY Chart
Eli Lilly: Another Not-To-Miss Dip
Eli Lilly's price fell with a thud yesterday following underwhelming drug trial results as the markets completely ignored strong Q2 2025 results. LLY's drop is immediately reminiscent of a similar plunge for its rival Novo Nordisk a few days ago, and also only makes for a stronger Buy case. The company's position in the weight management market remains undisputed for now; it's also reported robust financials in Q2 2025 along with upgraded guidance.
Is Eli Lilly's 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Industry pioneer Novo Nordisk A/S NYSE: NVO saw its stock drop nearly 22% on July 29 after lowering its full-year guidance. Then, on Aug. 7, Eli Lilly NYSE: LLY shares fell approximately 14%.
Eli Lilly: 50% Upside For LLY Stock?
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This positive performance was mainly fueled by the ongoing success of its medications, Mounjaro and Zepbound.
ELI LILLY Dividends
 LLY In 4 days Announced | Quarterly | $1.5 Per Share |
| LLY 2 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 5 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 8 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 11 months ago Paid | Quarterly | $1.3 Per Share |
ELI LILLY Earnings
| 30 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 29 Oct 2025 (In 2 months) Date | | 6.31 Cons. EPS | - EPS |
| 28 Oct 2025 (In 2 months) Date | | 6.14 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 5.56 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 5.56 Cons. EPS | 6.31 EPS |
| LLY In 4 days Announced | Quarterly | $1.5 Per Share |
| LLY 2 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 5 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 8 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 11 months ago Paid | Quarterly | $1.3 Per Share |
| 30 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 29 Oct 2025 (In 2 months) Date | | 6.31 Cons. EPS | - EPS |
| 28 Oct 2025 (In 2 months) Date | | 6.14 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 5.56 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 5.56 Cons. EPS | 6.31 EPS |
ELI LILLY (LLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has ELI LILLY ever had a stock split?
ELI LILLY Profile
| Drug Manufacturers - General Industry | Healthcare Sector | David A. Ricks CEO | XHAN Exchange | US5324571083 ISIN |
| US Country | 47,000 Employees | 15 Aug 2025 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
